Polymorphic control of inhalation microparticles prepared by crystallization

International Journal of Pharmaceutics

Volumn 361, Issue 1-2, 2008, Pages 141-149

  Murnane, Darragh ^a   Marriott, Christopher ^a   Martin, Gary P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aerosol; Antisolvent micronization; Differential scanning calorimetry; Inhalation; Polymorphism; Salmeterol xinafoate; Thermal kinetic analysis

Indexed keywords

2 PROPANOL; MACROGOL; MACROGOL 400; MACROGOL 6000; SALMETEROL XINAFOATE; SOLVENT;

ARTICLE; COOLING; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; ENANTIOMER; INHALATION; KINETICS; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; SOLID STATE; THERMAL ANALYSIS; X RAY POWDER DIFFRACTION;

2-PROPANOL; ADMINISTRATION, INHALATION; ALBUTEROL; BRONCHODILATOR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; MICROSPHERES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POWDER DIFFRACTION; SOLVENTS;

EID: 47949124171     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.05.033     Document Type: Article

References (45)

1. Avrami M. Kinetics of phase change I-general theory. J. Chem. Phys. 7 (1939) 1103-1112
2. Avrami M. Kinetics of phase change. II. Transformation-time relations for random distribution of nuclei. J. Chem. Phys. 8 (1940) 212-224
3. Avrami M. Granulation, phase change, and microstructure-kinetics of phase change III. J. Chem. Phys. 9 (1941) 177-184
4. Beach S., Latham D., Sidgwick C., Hanna M., and York P. Control of the physical form of salmeterol xinofoate. Org. Process Res. Dev. 3 (1999) 370-376
5. Bernstein J., Davey R.J., and Henck J.O. Concomitant polymorphs. Angew. Chem. 38 (1999) 3440-3461
6. Blagden N., and Davey R.J. Polymorph selection: challenges for the future?. Cryst. Growth Des. 3 (2003) 873-885
7. Brittain H.G. Effects of mechanical processing on phase composition. J. Pharm. Sci. 91 (2002) 1573-1580
8. Burger A., and Ramberger R. Polymorphism of pharmaceuticals and other molecular-crystals. 1. Theory of thermodynamic rules. Mikrochim. Acta 2 (1979) 259-271
9. Byard S.J., Jackson S.L., Smail A., Bauer M., and Apperley D.C. Studies on the crystallinity of a pharmaceutical development drug substance. J. Pharm. Sci. 94 (2005) 1321-1335
10. Chikhalia V., Forbes R.T., Storey R.A., and Ticehurst M. The effect of crystal morphology and mill type on milling induced crystal disorder. Eur. J. Pharm. Sci. 27 (2006) 19-26
11. Chung K.F., and O'Byrne P.M. Pharmacological agents used to treat asthma. Eur. Respir. Monogr. (2003) 339-375
12. Dunitz J. Phase changes and chemical reactions in molecular crystals. Acta Crystallogr. B 51 (1995) 619-631
13. Elamin A.A., Ahlneck C., Alderborn G., and Nystrom C. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int. J. Pharm. 111 (1994) 159-170
14. Giacovazzo C. Direct methods and powder data: state of the art and perspectives. Acta Crystallogr. A 52 (1996) 331-339
15. Heng J.Y.Y., Thielmann F., and Williams D.R. The effects of milling on the surface properties of form I paracetamol crystals. Pharm. Res. 23 (2006) 1918-1927
16. Kaschiev D. Nucleation: Basic Theory with Applications. 1st ed. (2000), Butterworth-Heinemann, Oxford
17. Langford J.I., and Louer D. Powder diffraction. Rep. Progress Phys. 59 (1996) 131-234
18. Mackin L., Sartnurak S., Thomas I., and Moore S. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation. Int. J. Pharm. 231 (2002) 213-226
19. Mackin L., Zanon R., Park J.M., Foster K., Opalenik H., and Demonte M. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. Int. J. Pharm. 231 (2002) 227-236
20. Michaelsen C., and Dahms M. On the determination of nucleation and growth kinetics by calorimetry. Thermochim. Acta 288 (1996) 9-27
21. Morris K.R., Griesser U.J., Eckhardt C.J., and Stowell J.G. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv. Drug Del. Rev. 48 (2001) 91-114
22. Murnane D., Marriott C., and Martin G.P. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization. Eur. J. Pharm. Biopharm. 69 (2008) 94-105
23. Murnane D., Martin G.P., and Marriott C. Developing an environmentally benign process for the production of microparticles: amphiphilic crystallization. Eur. J. Pharm. Biopharm. 69 (2008) 72-82
24. Planinsek O., and Buckton G. Inverse gas chromatography: considerations about appropriate use for amorphous and crystalline powders. J. Pharm. Sci. 92 (2003) 1286-1294
25. Pritchard J.N. The influence of lung deposition on clinical response. J. Aerosol Med. 14 (2001) S19-S26
26. Rehman M., Shekunov B.Y., York P., Lechuga-Ballesteros D., Miller D.P., Tan T., and Colthorpe P. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur. J. Pharm. Sci. 22 (2004) 1-17
27. Rodriguez-Hornedo N., and Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 88 (1999) 651-660
28. Sato K. Polymorphic transformations in crystal-growth. J. Phys. D: Appl. Phys. 26 (1993) B77-B84
29. Shah B., Kakumanu V.K., and Bansal A.K. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J. Pharm. Sci. 95 (2006) 1641-1665
30. Shekunov B.Y., Feeley J.C., Chow A.H.L., Tong H.H.Y., and York P. Physical properties of supercritically-processed and micronised powders for respiratory drug delivery. "KONA" Powder Sci. Technol. Jpn. (2002) 178-187
31. Shekunov B.Y., and York P. Crystallization processes in pharmaceutical technology and drug delivery design. J. Cryst. Growth 211 (2000) 122-136
32. Sonnergaard J.M. On the misinterpretation of the correlation coefficient in pharmaceutical sciences. Int. J. Pharm. 321 (2006) 12-17
33. Steckel H., Rasenack N., Villax P., and Muller B.W. In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate. Int. J. Pharm. 258 (2003) 65-75
34. ter Horst J.H., Kramer H.J.M., and Jansens P.J. A new molecular modeling approach to predict concomitant nucleation of polymorphs. Cryst. Growth Des. 2 (2002) 351-356
35. Threlfall T. Crystallisation of polymorphs: thermodynamic insight into the role of solvent. Org. Process Res. Dev. 4 (2000) 384-390
36. Tong H.H., Shekunov B.Y., York P., and Chow A.H. Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids. Pharm. Res. 18 (2001) 852-858
37. Tong H.H.Y., Shekunov B.Y., York P., and Chow A.H.L. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm. Res. 19 (2002) 640-648
38. Tong H.H.Y., Shekunov B.Y., York P., and Chow A.H.L. Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples. Pharm. Res. 20 (2003) 1423-1429
39. Tong H.H.Y., Shekunov B.Y., York P., and Chow A.H.L. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography. J. Pharm. Sci. 95 (2006) 228-233
40. 0.50 alloy. J. Phys. Chem. Solids 61 (2000) 493-500
41. Vyazovkin S., and Wight C.A. Kinetics in solids. Annu. Rev. Phys. Chem. 48 (1997) 125-149
42. Ward G.H., and Schultz R.K. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12 (1995) 773-779
43. York P., Ticehurst M.D., Osborn J.C., Roberts R.J., and Rowe R.C. Characterisation of the surface energetics of milled dl-propranolol hydrochloride using inverse gas chromatography and molecular modelling. Int. J. Pharm. 174 (1998) 179-186
44. Zhang G.G.Z., Law D., Schmitt E.A., and Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug Del. Rev. 56 (2004) 371-390
45. Zhou D.L., Schmitt E.A., Zhang G.G., Law D., Vyazovkin S., Wight C.A., and Grant D.J.W. Crystallization kinetics of amorphous nifedipine studied by model-fitting and model-free approaches. J. Pharm. Sci. 92 (2003) 1779-1792